锕和铋靶向α治疗概述
An Overview of Targeted Alpha Therapy with Actinium and Bismuth.
作者信息
Morgenstern Alfred, Apostolidis Christos, Kratochwil Clemens, Sathekge Mike, Krolicki Leszek, Bruchertseifer Frank
机构信息
European Commission, Joint Research Centre, Directorate for Nuclear Safety and Security, Karlsruhe, Germany.
Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany.
出版信息
Curr Radiopharm. 2018;11(3):200-208. doi: 10.2174/1874471011666180502104524.
BACKGROUND
Recent reports of the remarkable therapeutic efficacy of 225Ac-labeled PSMA- 617 for therapy of metastatic castration-resistant prostate cancer have underlined the clinical potential of targeted alpha therapy.
OBJECTIVE AND CONCLUSION
This review describes methods for the production of 225Ac and its daughter nuclide 213Bi and summarizes the current clinical experience with both alpha emitters with particular focus on recent studies of targeted alpha therapy of bladder cancer, brain tumors, neuroendocrine tumors and prostate cancer.
背景
近期关于225Ac标记的PSMA-617治疗转移性去势抵抗性前列腺癌具有显著疗效的报道突显了靶向α治疗的临床潜力。
目的与结论
本综述描述了225Ac及其子核素213Bi的生产方法，并总结了这两种α发射体目前的临床经验，特别关注膀胱癌、脑肿瘤、神经内分泌肿瘤和前列腺癌靶向α治疗的近期研究。
Zotero 插件